Belantamab Mafodotin-blmf Injection

Generic name: Pronounced as (bel an' ta mab) (ma" foe doe' tin)
Brand names
  • Blenrep®
Click on drug name to hear pronunciation

Medical Content Reviewed By HelloPharmacist Staff

Last Revised - 09/15/2020

Belantamab mafodotin-blmf injection may cause serious eye or vision problems, including vision loss. Tell your doctor if you have or have a history of vision or eye problems. If you experience any of the following symptoms, call your doctor immediately: blurred vision, vision changes or loss, or dry eyes.

Because of the risk of vision problems with this medication, belantamab mafodotin-blmf is only available through a special program called Blenrep REMS®. You, your doctor, and your healthcare facility must be enrolled in this program before you can receive belantamab mafodotin-blmf. Ask your doctor for more information about this program.

Do not wear contact lenses during treatment unless directed by a doctor or eye doctor. Use a preservative-free lubricant eye drop as directed by your doctor during your treatment.

Do not drive a car or operate machinery until you know how this medication affects your vision.

Keep all appointments with your doctor and the laboratory. Your doctor will order certain tests before and during your treatment. Your doctor will order an eye exam before and several times during your treatment, especially if you notice a change in vision.

Your doctor or pharmacist will give you the manufacturer's patient information sheet (Medication Guide) when you begin treatment with belantamab mafodotin-blmf and each time you refill your prescription. Read the information carefully and ask your doctor or pharmacist if you have any questions. You can also visit the Food and Drug Administration (FDA) website (http://www.fda.gov/Drugs/DrugSafety/ucm085729.htm) or the manufacturer's website to obtain the Medication Guide.

Talk to your doctor about the risks of receiving belantamab mafodotin-blmf.

Belantamab mafodotin-blmf injection is used to treat multiple myeloma (a type of cancer of the bone marrow) that has returned or has not improved in adults who have received at least 4 other medications. Belantamab mafodotin-blmf is in a class of medications called antibody-drug conjugates. It works by killing cancer cells.

Belantamab mafodotin-blmf comes as a powder to be mixed with liquid and injected intravenously (into a vein) over 30 minutes by a doctor or nurse in a hospital or medical facility. It is usually given once every 3 weeks. The cycle may be repeated as recommended by your doctor. The length of your treatment depends on how well your body responds to the medication and any side effects that you experience.

A doctor or nurse will watch you closely while you are receiving the medication to be sure you are not having a serious reaction to the medication. Tell your doctor or nurse immediately if you experience any of the following symptoms: chills; flushing; itching or rash; shortness of breath, cough, or wheezing; tiredness; fever; dizziness or lightheadedness; or swelling of your lips, tongue, throat, or face.

Your doctor may reduce your dose or temporarily or permanently stop your treatment. This depends on how well the medication works for you and the side effects you experience. Be sure to tell your doctor how you are feeling during your treatment with belantamab mafodotin-blmf.

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

Before receiving belantamab mafodotin-blmf injection,

  • tell your doctor and pharmacist if you are allergic to belantamab mafodotin-blmf, any other medications, or any of the ingredients in belantamab mafodotin-blmf injection. Ask your pharmacist or check the Medication Guide for a list of the ingredients.

  • tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.

  • tell your doctor if you have or have ever had bleeding problems.

  • tell your doctor if you are pregnant, plan to become pregnant, or plan to father a child. You should not start receiving belantamab mafodotin-blmf injection until a pregnancy test has shown that you are not pregnant. If you are a woman who is able to become pregnant, you must use effective birth control during your treatment and for 4 months after your final dose. If you are male with a female partner who could become pregnant, you must use effective birth control during your treatment and for 6 months after your final dose. Talk to your doctor about methods of birth control that will work for you. If you or your partner become pregnant while receiving belantamab mafodotin-blmf injection, call your doctor. Belantamab mafodotin-blmf injection may harm the fetus.

  • tell your doctor if you are breastfeeding. Do not breastfeed during your treatment and for 3 months after your final dose.

  • you should know that this medication may decrease fertility in men and women. Talk to your doctor about the risks of receiving belantamab mafodotin-blmf injection.

Unless your doctor tells you otherwise, continue your normal diet.

If you miss an appointment to receive a dose of belantamab mafodotin-blmf, call your doctor right away.

  • Belantamab mafodotin-blmf may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

    • nausea

    • constipation

    • diarrhea

    • loss of appetite

    • joint or back pain

    • tiredness

  • Some side effects can be serious. If you experience any of these symptoms or those listed in the IMPORTANT WARNING section, call your doctor immediately or get emergency medical treatment:

    • unusual bleeding or bruising

  • Belantamab mafodotin-blmf may cause other side effects. Call your doctor if you have any unusual problems while receiving this medication.

  • If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.

Ask your pharmacist any questions you have about belantamab mafodotin-blmf.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

Drug Interaction
Repaglinide Repaglinide Repaglinide may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Atorvastatin Atorvastatin Atorvastatin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Candesartan Candesartan The excretion of Belantamab mafodotin can be decreased when combined with Candesartan.
Erythromycin and Sulfisoxazole Erythromycin and Sulfisoxazole Erythromycin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Estrogen and Progestin (Oral Contraceptives) Estrogen and Progestin (Oral Contraceptives) Conjugated estrogens may increase the thrombogenic activities of Belantamab mafodotin.
Fenofibrate Fenofibrate Fenofibrate may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Paregoric Paregoric The serum concentration of Belantamab mafodotin can be increased when it is combined with Morphine.
Reserpine Reserpine Reserpine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Tacrolimus Tacrolimus The serum concentration of Belantamab mafodotin can be increased when it is combined with Tacrolimus.
Fluconazole Injection Fluconazole Injection The serum concentration of Belantamab mafodotin can be increased when it is combined with Fluconazole.
Morphine Injection Morphine Injection The serum concentration of Belantamab mafodotin can be increased when it is combined with Morphine.
Cyclosporine Cyclosporine Cyclosporine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Pantoprazole Pantoprazole The excretion of Belantamab mafodotin can be decreased when combined with Pantoprazole.
Telmisartan Telmisartan Telmisartan may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Trimipramine Trimipramine The serum concentration of Trimipramine can be increased when it is combined with Belantamab mafodotin.
Tenofovir Tenofovir The serum concentration of Belantamab mafodotin can be increased when it is combined with Tenofovir.
Sirolimus Sirolimus The serum concentration of Belantamab mafodotin can be increased when it is combined with Sirolimus.
Olmesartan Olmesartan Olmesartan may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Zonisamide Zonisamide The serum concentration of Belantamab mafodotin can be increased when it is combined with Zonisamide.
Adalimumab Injection Adalimumab Injection The risk or severity of adverse effects can be increased when Adalimumab is combined with Belantamab mafodotin.
Ezetimibe Ezetimibe Ezetimibe may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Atazanavir Atazanavir Atazanavir may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Omalizumab Injection Omalizumab Injection The risk or severity of adverse effects can be increased when Omalizumab is combined with Belantamab mafodotin.
Rosuvastatin Rosuvastatin Rosuvastatin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Vardenafil Vardenafil The serum concentration of Belantamab mafodotin can be increased when it is combined with Vardenafil.
Tegaserod Tegaserod The serum concentration of Belantamab mafodotin can be increased when it is combined with Tegaserod.
Progesterone Progesterone Progesterone may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Infliximab Injection Infliximab Injection The risk or severity of adverse effects can be increased when Infliximab is combined with Belantamab mafodotin.
Tinidazole Tinidazole Tinidazole may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Bosentan Bosentan Bosentan may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Natalizumab Injection Natalizumab Injection The risk or severity of adverse effects can be increased when Natalizumab is combined with Belantamab mafodotin.
Tipranavir Tipranavir Tipranavir may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Ranolazine Ranolazine The serum concentration of Belantamab mafodotin can be increased when it is combined with Ranolazine.
Imatinib Imatinib Imatinib may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Sitagliptin Sitagliptin The serum concentration of Belantamab mafodotin can be increased when it is combined with Sitagliptin.
Bevacizumab Injection Bevacizumab Injection The risk or severity of adverse effects can be increased when Bevacizumab is combined with Belantamab mafodotin.
Paliperidone Paliperidone The serum concentration of Belantamab mafodotin can be increased when it is combined with Paliperidone.
Bortezomib Bortezomib The serum concentration of Bortezomib can be increased when it is combined with Belantamab mafodotin.
Posaconazole Posaconazole The serum concentration of Belantamab mafodotin can be increased when it is combined with Posaconazole.
Rituximab Injection Rituximab Injection The risk or severity of adverse effects can be increased when Rituximab is combined with Belantamab mafodotin.
Cetuximab Injection Cetuximab Injection The risk or severity of adverse effects can be increased when Cetuximab is combined with Belantamab mafodotin.
Darunavir Darunavir The excretion of Belantamab mafodotin can be decreased when combined with Darunavir.
Ranibizumab Injection Ranibizumab Injection The risk or severity of adverse effects can be increased when Ranibizumab is combined with Belantamab mafodotin.
Sorafenib Sorafenib The serum concentration of Belantamab mafodotin can be increased when it is combined with Sorafenib.
Lapatinib Lapatinib The serum concentration of Belantamab mafodotin can be increased when it is combined with Lapatinib.
Dasatinib Dasatinib The serum concentration of Dasatinib can be increased when it is combined with Belantamab mafodotin.
Panitumumab Injection Panitumumab Injection The risk or severity of adverse effects can be increased when Panitumumab is combined with Belantamab mafodotin.
Ivermectin Ivermectin The excretion of Belantamab mafodotin can be decreased when combined with Ivermectin.
Temsirolimus Temsirolimus The serum concentration of Belantamab mafodotin can be increased when it is combined with Temsirolimus.
Nilotinib Nilotinib The serum concentration of Belantamab mafodotin can be increased when it is combined with Nilotinib.
Toremifene Toremifene The serum concentration of Belantamab mafodotin can be increased when it is combined with Toremifene.
Budesonide Budesonide Budesonide may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Bendamustine Injection Bendamustine Injection The serum concentration of Bendamustine can be increased when it is combined with Belantamab mafodotin.
Certolizumab Injection Certolizumab Injection The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Belantamab mafodotin.
Irinotecan Injection Irinotecan Injection The excretion of Belantamab mafodotin can be decreased when combined with Irinotecan.
Alemtuzumab Injection (Chronic Lymphocytic Leukemia) Alemtuzumab Injection (Chronic Lymphocytic Leukemia) The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Belantamab mafodotin.
Silodosin Silodosin The serum concentration of Belantamab mafodotin can be increased when it is combined with Silodosin.
Eltrombopag Eltrombopag The excretion of Belantamab mafodotin can be decreased when combined with Eltrombopag.
Ibritumomab Injection Ibritumomab Injection The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Belantamab mafodotin.
Everolimus Everolimus The serum concentration of Belantamab mafodotin can be increased when it is combined with Everolimus.
Tolvaptan (low blood sodium) Tolvaptan (low blood sodium) The serum concentration of Tolvaptan can be increased when it is combined with Belantamab mafodotin.
Dronedarone Dronedarone The serum concentration of Belantamab mafodotin can be increased when it is combined with Dronedarone.
Romidepsin Injection Romidepsin Injection The serum concentration of Romidepsin can be increased when it is combined with Belantamab mafodotin.
Topotecan Topotecan The serum concentration of Topotecan can be increased when it is combined with Belantamab mafodotin.
Ofatumumab Injection (Chronic Lymphocytic Leukemia) Ofatumumab Injection (Chronic Lymphocytic Leukemia) The risk or severity of adverse effects can be increased when Ofatumumab is combined with Belantamab mafodotin.
Golimumab Injection Golimumab Injection The risk or severity of adverse effects can be increased when Golimumab is combined with Belantamab mafodotin.
Pazopanib Pazopanib The serum concentration of Belantamab mafodotin can be increased when it is combined with Pazopanib.
Pitavastatin Pitavastatin Pitavastatin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Denosumab Injection Denosumab Injection The risk or severity of adverse effects can be increased when Denosumab is combined with Belantamab mafodotin.
Tocilizumab Injection Tocilizumab Injection The risk or severity of adverse effects can be increased when Tocilizumab is combined with Belantamab mafodotin.
Cabazitaxel Injection Cabazitaxel Injection The serum concentration of Belantamab mafodotin can be increased when it is combined with Cabazitaxel.
Ustekinumab Injection Ustekinumab Injection The risk or severity of adverse effects can be increased when Ustekinumab is combined with Belantamab mafodotin.
Ipilimumab Injection Ipilimumab Injection The risk or severity of adverse effects can be increased when Ipilimumab is combined with Belantamab mafodotin.
Belimumab Injection Belimumab Injection The risk or severity of adverse effects can be increased when Belimumab is combined with Belantamab mafodotin.
Linagliptin Linagliptin The serum concentration of Belantamab mafodotin can be increased when it is combined with Linagliptin.
Rilpivirine Rilpivirine The excretion of Belantamab mafodotin can be decreased when combined with Rilpivirine.
Telaprevir Telaprevir The serum concentration of Belantamab mafodotin can be increased when it is combined with Glecaprevir.
Rivaroxaban Rivaroxaban The serum concentration of Belantamab mafodotin can be increased when it is combined with Rivaroxaban.
Ticagrelor Ticagrelor The serum concentration of Belantamab mafodotin can be increased when it is combined with Ticagrelor.
Brentuximab Vedotin Injection Brentuximab Vedotin Injection The serum concentration of Belantamab mafodotin can be increased when it is combined with Brentuximab vedotin.
Vandetanib Vandetanib The serum concentration of Belantamab mafodotin can be increased when it is combined with Vandetanib.
Clobazam Clobazam The serum concentration of Belantamab mafodotin can be increased when it is combined with Clobazam.
Vemurafenib Vemurafenib The serum concentration of Belantamab mafodotin can be increased when it is combined with Vemurafenib.
Ivacaftor Ivacaftor The serum concentration of Belantamab mafodotin can be increased when it is combined with Ivacaftor.
Basiliximab Injection Basiliximab Injection The risk or severity of adverse effects can be increased when Basiliximab is combined with Belantamab mafodotin.
Axitinib Axitinib The serum concentration of Belantamab mafodotin can be increased when it is combined with Axitinib.
Crizotinib Crizotinib The serum concentration of Belantamab mafodotin can be increased when it is combined with Crizotinib.
Cabergoline Cabergoline The serum concentration of Cabergoline can be increased when it is combined with Belantamab mafodotin.
Ambrisentan Ambrisentan The serum concentration of Belantamab mafodotin can be increased when it is combined with Ambrisentan.
Eculizumab Injection Eculizumab Injection The risk or severity of adverse effects can be increased when Eculizumab is combined with Belantamab mafodotin.
Pertuzumab Injection Pertuzumab Injection The risk or severity of adverse effects can be increased when Pertuzumab is combined with Belantamab mafodotin.
Carfilzomib Injection Carfilzomib Injection The serum concentration of Belantamab mafodotin can be increased when it is combined with Carfilzomib.
Enzalutamide Enzalutamide The serum concentration of Belantamab mafodotin can be increased when it is combined with Enzalutamide.
Mirabegron Mirabegron The serum concentration of Belantamab mafodotin can be increased when it is combined with Mirabegron.
Regorafenib Regorafenib The serum concentration of Belantamab mafodotin can be increased when it is combined with Regorafenib.
Bosutinib Bosutinib The serum concentration of Bosutinib can be increased when it is combined with Belantamab mafodotin.
Teriflunomide Teriflunomide The excretion of Belantamab mafodotin can be decreased when combined with Teriflunomide.
Ponatinib Ponatinib The serum concentration of Belantamab mafodotin can be increased when it is combined with Ponatinib.
Pomalidomide Pomalidomide The serum concentration of Pomalidomide can be increased when it is combined with Belantamab mafodotin.
Ado-trastuzumab Emtansine Injection Ado-trastuzumab Emtansine Injection The serum concentration of Belantamab mafodotin can be increased when it is combined with Trastuzumab emtansine.
Apixaban Apixaban The serum concentration of Belantamab mafodotin can be increased when it is combined with Apixaban.
Canagliflozin Canagliflozin The serum concentration of Belantamab mafodotin can be increased when it is combined with Canagliflozin.
Dabrafenib Dabrafenib The serum concentration of Belantamab mafodotin can be increased when it is combined with Dabrafenib.
Dolutegravir Dolutegravir The serum concentration of Belantamab mafodotin can be increased when it is combined with Dolutegravir.
Afatinib Afatinib The serum concentration of Belantamab mafodotin can be increased when it is combined with Afatinib.
Lomitapide Lomitapide The serum concentration of Belantamab mafodotin can be increased when it is combined with Lomitapide.
Obinutuzumab Injection Obinutuzumab Injection The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Belantamab mafodotin.
Simeprevir Simeprevir Simeprevir may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Sofosbuvir Sofosbuvir The serum concentration of Belantamab mafodotin can be increased when it is combined with Sofosbuvir.
Ramucirumab Injection Ramucirumab Injection The risk or severity of adverse effects can be increased when Ramucirumab is combined with Belantamab mafodotin.
Ceritinib Ceritinib The serum concentration of Ceritinib can be increased when it is combined with Belantamab mafodotin.
Siltuximab Injection Siltuximab Injection The risk or severity of adverse effects can be increased when Siltuximab is combined with Belantamab mafodotin.
Vedolizumab Injection Vedolizumab Injection The risk or severity of adverse effects can be increased when Vedolizumab is combined with Belantamab mafodotin.
Belinostat Injection Belinostat Injection The serum concentration of Belantamab mafodotin can be increased when it is combined with Belinostat.
Idelalisib Idelalisib The serum concentration of Belantamab mafodotin can be increased when it is combined with Idelalisib.
Vorapaxar Vorapaxar The serum concentration of Belantamab mafodotin can be increased when it is combined with Vorapaxar.
Suvorexant Suvorexant The serum concentration of Belantamab mafodotin can be increased when it is combined with Suvorexant.
Dulaglutide Injection Dulaglutide Injection The risk or severity of adverse effects can be increased when Dulaglutide is combined with Belantamab mafodotin.
Pembrolizumab Injection Pembrolizumab Injection The risk or severity of adverse effects can be increased when Pembrolizumab is combined with Belantamab mafodotin.
Edoxaban Edoxaban The serum concentration of Belantamab mafodotin can be increased when it is combined with Edoxaban.
Nivolumab Injection Nivolumab Injection The risk or severity of adverse effects can be increased when Nivolumab is combined with Belantamab mafodotin.
Blinatumomab Injection Blinatumomab Injection The risk or severity of adverse effects can be increased when Blinatumomab is combined with Belantamab mafodotin.
Caspofungin Injection Caspofungin Injection The excretion of Belantamab mafodotin can be decreased when combined with Caspofungin.
Nintedanib Nintedanib The serum concentration of Belantamab mafodotin can be increased when it is combined with Nintedanib.
Secukinumab Injection Secukinumab Injection The risk or severity of adverse effects can be increased when Secukinumab is combined with Belantamab mafodotin.
Palbociclib Palbociclib The serum concentration of Belantamab mafodotin can be increased when it is combined with Palbociclib.
Lenvatinib Lenvatinib Lenvatinib may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Panobinostat Panobinostat The serum concentration of Panobinostat can be increased when it is combined with Belantamab mafodotin.
Dinutuximab Injection Dinutuximab Injection The risk or severity of adverse effects can be increased when Dinutuximab is combined with Belantamab mafodotin.
Deoxycholic Acid Injection Deoxycholic Acid Injection Deoxycholic acid may increase the excretion rate of Belantamab mafodotin which could result in a lower serum level and potentially a reduction in efficacy.
Isavuconazonium Injection Isavuconazonium Injection The serum concentration of Belantamab mafodotin can be increased when it is combined with Isavuconazonium.
Alirocumab Injection Alirocumab Injection The risk or severity of adverse effects can be increased when Alirocumab is combined with Belantamab mafodotin.
Flibanserin Flibanserin The serum concentration of Belantamab mafodotin can be increased when it is combined with Flibanserin.
Rolapitant Rolapitant The serum concentration of Belantamab mafodotin can be increased when it is combined with Rolapitant.
Evolocumab Injection Evolocumab Injection The risk or severity of adverse effects can be increased when Evolocumab is combined with Belantamab mafodotin.
Daclatasvir Daclatasvir The serum concentration of Belantamab mafodotin can be increased when it is combined with Daclatasvir.
Eluxadoline Eluxadoline The excretion of Belantamab mafodotin can be decreased when combined with Eluxadoline.
Cobimetinib Cobimetinib The serum concentration of Belantamab mafodotin can be increased when it is combined with Cobimetinib.
Mepolizumab Injection Mepolizumab Injection The risk or severity of adverse effects can be increased when Mepolizumab is combined with Belantamab mafodotin.
Elotuzumab Injection Elotuzumab Injection The risk or severity of adverse effects can be increased when Elotuzumab is combined with Belantamab mafodotin.
Daratumumab Injection Daratumumab Injection The risk or severity of adverse effects can be increased when Daratumumab is combined with Belantamab mafodotin.
Osimertinib Osimertinib The serum concentration of Osimertinib can be increased when it is combined with Belantamab mafodotin.
Necitumumab Injection Necitumumab Injection The risk or severity of adverse effects can be increased when Necitumumab is combined with Belantamab mafodotin.
Dexamethasone Injection Dexamethasone Injection Dexamethasone may increase the excretion rate of Belantamab mafodotin which could result in a lower serum level and potentially a reduction in efficacy.
Reslizumab Injection Reslizumab Injection The risk or severity of adverse effects can be increased when Reslizumab is combined with Belantamab mafodotin.
Ixekizumab Injection Ixekizumab Injection The risk or severity of adverse effects can be increased when Ixekizumab is combined with Belantamab mafodotin.
Venetoclax Venetoclax The serum concentration of Belantamab mafodotin can be increased when it is combined with Venetoclax.
Cobicistat Cobicistat The serum concentration of Belantamab mafodotin can be increased when it is combined with Cobicistat.
Selexipag Selexipag The serum concentration of Belantamab mafodotin can be increased when it is combined with Selexipag.
Atezolizumab Injection Atezolizumab Injection The risk or severity of adverse effects can be increased when Atezolizumab is combined with Belantamab mafodotin.
Olaratumab Injection Olaratumab Injection The risk or severity of adverse effects can be increased when Olaratumab is combined with Belantamab mafodotin.
Rucaparib Rucaparib The serum concentration of Belantamab mafodotin can be increased when it is combined with Rucaparib.
Bezlotoxumab Injection Bezlotoxumab Injection The risk or severity of adverse effects can be increased when Bezlotoxumab is combined with Belantamab mafodotin.
Avelumab Injection Avelumab Injection The risk or severity of adverse effects can be increased when Avelumab is combined with Belantamab mafodotin.
Brodalumab Injection Brodalumab Injection The risk or severity of adverse effects can be increased when Brodalumab is combined with Belantamab mafodotin.
Dupilumab Injection Dupilumab Injection The risk or severity of adverse effects can be increased when Dupilumab is combined with Belantamab mafodotin.
Ocrelizumab Injection Ocrelizumab Injection The risk or severity of adverse effects can be increased when Ocrelizumab is combined with Belantamab mafodotin.
Durvalumab Injection Durvalumab Injection The risk or severity of adverse effects can be increased when Durvalumab is combined with Belantamab mafodotin.
Sarilumab Injection Sarilumab Injection The risk or severity of adverse effects can be increased when Sarilumab is combined with Belantamab mafodotin.
Neratinib Neratinib The serum concentration of Belantamab mafodotin can be increased when it is combined with Neratinib.
Guselkumab Injection Guselkumab Injection The risk or severity of adverse effects can be increased when Guselkumab is combined with Belantamab mafodotin.
Enasidenib Enasidenib The serum concentration of Belantamab mafodotin can be increased when it is combined with Enasidenib.
Inotuzumab Ozogamicin Injection Inotuzumab Ozogamicin Injection The serum concentration of Belantamab mafodotin can be increased when it is combined with Inotuzumab ozogamicin.
Copanlisib Injection Copanlisib Injection The serum concentration of Copanlisib can be increased when it is combined with Belantamab mafodotin.
Abemaciclib Abemaciclib The serum concentration of Abemaciclib can be increased when it is combined with Belantamab mafodotin.
Betrixaban Betrixaban The serum concentration of Belantamab mafodotin can be increased when it is combined with Betrixaban.
Benralizumab Injection Benralizumab Injection The risk or severity of adverse effects can be increased when Benralizumab is combined with Belantamab mafodotin.
Gemtuzumab Ozogamicin Injection Gemtuzumab Ozogamicin Injection The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Belantamab mafodotin.
Letermovir Letermovir Letermovir may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Ertugliflozin Ertugliflozin The serum concentration of Belantamab mafodotin can be increased when it is combined with Ertugliflozin.
Apalutamide Apalutamide The serum concentration of Belantamab mafodotin can be decreased when it is combined with Apalutamide.
Ibalizumab-uiyk Injection Ibalizumab-uiyk Injection The risk or severity of adverse effects can be increased when Ibalizumab is combined with Belantamab mafodotin.
Tildrakizumab-asmn injection Tildrakizumab-asmn injection The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Belantamab mafodotin.
Erenumab-aooe Injection Erenumab-aooe Injection The risk or severity of adverse effects can be increased when Erenumab is combined with Belantamab mafodotin.
Avatrombopag Avatrombopag The serum concentration of Belantamab mafodotin can be increased when it is combined with Avatrombopag.
Baricitinib Baricitinib The serum concentration of Belantamab mafodotin can be increased when it is combined with Baricitinib.
Burosumab-twza Injection Burosumab-twza Injection The risk or severity of adverse effects can be increased when Burosumab is combined with Belantamab mafodotin.
Eliglustat Eliglustat The serum concentration of Belantamab mafodotin can be increased when it is combined with Eliglustat.
Binimetinib Binimetinib The serum concentration of Binimetinib can be increased when it is combined with Belantamab mafodotin.
Ivosidenib Ivosidenib The serum concentration of Belantamab mafodotin can be increased when it is combined with Ivosidenib.
Lusutrombopag Lusutrombopag The serum concentration of Belantamab mafodotin can be increased when it is combined with Lusutrombopag.
Elagolix Elagolix The serum concentration of Belantamab mafodotin can be increased when it is combined with Elagolix.
Cemiplimab-rwlc Injection Cemiplimab-rwlc Injection The risk or severity of adverse effects can be increased when Cemiplimab is combined with Belantamab mafodotin.
Dacomitinib Dacomitinib The serum concentration of Belantamab mafodotin can be increased when it is combined with Dacomitinib.
Duvelisib Duvelisib The serum concentration of Belantamab mafodotin can be increased when it is combined with Duvelisib.
Galcanezumab-gnlm Injection Galcanezumab-gnlm Injection The risk or severity of adverse effects can be increased when Galcanezumab is combined with Belantamab mafodotin.
Mogamulizumab-kpkc Injection Mogamulizumab-kpkc Injection The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Belantamab mafodotin.
Omadacycline Omadacycline The serum concentration of Belantamab mafodotin can be increased when it is combined with Omadacycline.
Sarecycline Sarecycline The serum concentration of Belantamab mafodotin can be increased when it is combined with Sarecycline.
Talazoparib Talazoparib The serum concentration of Talazoparib can be increased when it is combined with Belantamab mafodotin.
Gilteritinib Gilteritinib The serum concentration of Belantamab mafodotin can be increased when it is combined with Gilteritinib.
Glasdegib Glasdegib The serum concentration of Belantamab mafodotin can be increased when it is combined with Glasdegib.
Larotrectinib Larotrectinib The serum concentration of Belantamab mafodotin can be increased when it is combined with Larotrectinib.
Paclitaxel (with albumin) Injection Paclitaxel (with albumin) Injection Paclitaxel may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Rifamycin Rifamycin The serum concentration of Belantamab mafodotin can be increased when it is combined with Rifamycin.
Ravulizumab-cwvz Injection Ravulizumab-cwvz Injection The risk or severity of adverse effects can be increased when Ravulizumab is combined with Belantamab mafodotin.
Emapalumab-lzsg Injection Emapalumab-lzsg Injection The risk or severity of adverse effects can be increased when Emapalumab is combined with Belantamab mafodotin.
Romosozumab-aqqg Injection Romosozumab-aqqg Injection The risk or severity of adverse effects can be increased when Romosozumab is combined with Belantamab mafodotin.
Caplacizumab-yhdp Injection Caplacizumab-yhdp Injection The risk or severity of adverse effects can be increased when Caplacizumab is combined with Belantamab mafodotin.
Erdafitinib Erdafitinib The serum concentration of Belantamab mafodotin can be increased when it is combined with Erdafitinib.
Risankizumab-rzaa Injection Risankizumab-rzaa Injection The risk or severity of adverse effects can be increased when Risankizumab is combined with Belantamab mafodotin.
Polatuzumab vedotin-piiq Injection Polatuzumab vedotin-piiq Injection The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Belantamab mafodotin.
Selinexor Selinexor The excretion of Belantamab mafodotin can be decreased when combined with Selinexor.
Darolutamide Darolutamide The serum concentration of Belantamab mafodotin can be increased when it is combined with Darolutamide.
Entrectinib Entrectinib The serum concentration of Belantamab mafodotin can be increased when it is combined with Entrectinib.
Pexidartinib Pexidartinib The excretion of Belantamab mafodotin can be decreased when combined with Pexidartinib.
Istradefylline Istradefylline The serum concentration of Belantamab mafodotin can be increased when it is combined with Istradefylline.
Pitolisant Pitolisant The serum concentration of Belantamab mafodotin can be increased when it is combined with Pitolisant.
Fedratinib Fedratinib The serum concentration of Belantamab mafodotin can be increased when it is combined with Fedratinib.
Lefamulin Lefamulin The serum concentration of Belantamab mafodotin can be increased when it is combined with Lefamulin.
Brolucizumab-dbll Injection Brolucizumab-dbll Injection The risk or severity of adverse effects can be increased when Brolucizumab is combined with Belantamab mafodotin.
Enfortumab vedotin-ejfv Injection Enfortumab vedotin-ejfv Injection The serum concentration of Belantamab mafodotin can be increased when it is combined with Enfortumab vedotin.
Fam-trastuzumab deruxtecan-nxki Injection Fam-trastuzumab deruxtecan-nxki Injection The risk or severity of adverse effects can be increased when Trastuzumab deruxtecan is combined with Belantamab mafodotin.
Lasmiditan Lasmiditan The serum concentration of Belantamab mafodotin can be increased when it is combined with Lasmiditan.
Ubrogepant Ubrogepant The serum concentration of Belantamab mafodotin can be increased when it is combined with Ubrogepant.
Tazemetostat Tazemetostat The serum concentration of Belantamab mafodotin can be increased when it is combined with Tazemetostat.
Bempedoic Acid Bempedoic Acid The excretion of Belantamab mafodotin can be decreased when combined with Bempedoic acid.
Isatuximab-irfc Injection Isatuximab-irfc Injection The risk or severity of adverse effects can be increased when Isatuximab is combined with Belantamab mafodotin.
Teprotumumab-trbw Injection Teprotumumab-trbw Injection The risk or severity of adverse effects can be increased when Teprotumumab is combined with Belantamab mafodotin.
Selumetinib Selumetinib The serum concentration of Belantamab mafodotin can be increased when it is combined with Selumetinib.
Rimegepant Rimegepant The serum concentration of Belantamab mafodotin can be increased when it is combined with Rimegepant.
Tucatinib Tucatinib Tucatinib may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Remdesivir Injection Remdesivir Injection The serum concentration of Belantamab mafodotin can be increased when it is combined with Remdesivir.
Sacituzumab govitecan-hziy Injection Sacituzumab govitecan-hziy Injection The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Belantamab mafodotin.
Ripretinib Ripretinib The serum concentration of Belantamab mafodotin can be increased when it is combined with Ripretinib.
Lemborexant Lemborexant The serum concentration of Belantamab mafodotin can be increased when it is combined with Lemborexant.
Luspatercept-aamt Injection Luspatercept-aamt Injection The risk or severity of adverse effects can be increased when Luspatercept is combined with Belantamab mafodotin.
Fostemsavir Fostemsavir The serum concentration of Belantamab mafodotin can be increased when it is combined with Fostemsavir.
Tafasitamab-cxix Injection Tafasitamab-cxix Injection The risk or severity of adverse effects can be increased when Tafasitamab is combined with Belantamab mafodotin.
Pralsetinib Pralsetinib Pralsetinib may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Margetuximab-cmkb Injection Margetuximab-cmkb Injection The risk or severity of adverse effects can be increased when Margetuximab is combined with Belantamab mafodotin.
Evinacumab-dgnb Injection Evinacumab-dgnb Injection The risk or severity of adverse effects can be increased when Evinacumab is combined with Belantamab mafodotin.
Aducanumab-avwa Injection Aducanumab-avwa Injection The risk or severity of adverse effects can be increased when Aducanumab is combined with Belantamab mafodotin.
Anifrolumab-fnia Injection Anifrolumab-fnia Injection The risk or severity of adverse effects can be increased when Anifrolumab is combined with Belantamab mafodotin.
Indomethacin Indomethacin Indomethacin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Naproxen Naproxen Naproxen may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Phenobarbital Phenobarbital Phenobarbital may increase the excretion rate of Belantamab mafodotin which could result in a lower serum level and potentially a reduction in efficacy.
Chlorpromazine Chlorpromazine Chlorpromazine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Sulfasalazine Sulfasalazine The excretion of Belantamab mafodotin can be decreased when combined with Sulfasalazine.
Doxorubicin Doxorubicin Doxorubicin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Dactinomycin Dactinomycin The serum concentration of Dactinomycin can be increased when it is combined with Belantamab mafodotin.
Cimetidine Cimetidine Cimetidine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Loperamide Loperamide The serum concentration of Belantamab mafodotin can be increased when it is combined with Loperamide.
Daunorubicin Daunorubicin Daunorubicin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Nitrofurantoin Nitrofurantoin Nitrofurantoin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Digoxin Digoxin Digoxin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Loxapine Loxapine The serum concentration of Belantamab mafodotin can be increased when it is combined with Loxapine.
Quinine Quinine The serum concentration of Belantamab mafodotin can be increased when it is combined with Quinine.
Sulfinpyrazone Sulfinpyrazone Sulfinpyrazone may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Imipramine Imipramine The serum concentration of Imipramine can be increased when it is combined with Belantamab mafodotin.
Quinidine Quinidine Quinidine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Rifampin Rifampin Rifampicin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Tamoxifen Tamoxifen Tamoxifen may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Levothyroxine Levothyroxine The excretion of Belantamab mafodotin can be decreased when combined with Levothyroxine.
Disulfiram Disulfiram Disulfiram may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Nortriptyline Nortriptyline The serum concentration of Nortriptyline can be increased when it is combined with Belantamab mafodotin.
Spironolactone Spironolactone Spironolactone may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Clomiphene Clomiphene The serum concentration of Belantamab mafodotin can be increased when it is combined with Clomifene.
Colchicine Colchicine The serum concentration of Belantamab mafodotin can be increased when it is combined with Colchicine.
Cefaclor Cefaclor Cefaclor may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Nystatin Nystatin The excretion of Belantamab mafodotin can be decreased when combined with Nystatin.
Ketoconazole Ketoconazole Ketoconazole may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Vincristine Injection Vincristine Injection Vincristine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Dipyridamole Dipyridamole Dipyridamole may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Vinblastine Vinblastine Vinblastine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Nifedipine Nifedipine Nifedipine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Verapamil Verapamil The serum concentration of Belantamab mafodotin can be increased when it is combined with Verapamil.
Atenolol Atenolol Atenolol may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Etoposide Etoposide The serum concentration of Etoposide can be increased when it is combined with Belantamab mafodotin.
Glyburide Glyburide Glyburide may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Glipizide Glipizide Glipizide may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Gemfibrozil Gemfibrozil The excretion of Belantamab mafodotin can be decreased when combined with Gemfibrozil.
Amiodarone Amiodarone The serum concentration of Belantamab mafodotin can be increased when it is combined with Amiodarone.
Lovastatin Lovastatin Lovastatin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Diclofenac Diclofenac Diclofenac may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Ofloxacin Ofloxacin Ofloxacin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Clarithromycin Clarithromycin The serum concentration of Belantamab mafodotin can be increased when it is combined with Clarithromycin.
Felodipine Felodipine Felodipine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Pravastatin Pravastatin Pravastatin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Simvastatin Simvastatin The serum concentration of Belantamab mafodotin can be increased when it is combined with Simvastatin.
Itraconazole Itraconazole The serum concentration of Belantamab mafodotin can be increased when it is combined with Itraconazole.
Bisoprolol Bisoprolol The serum concentration of Belantamab mafodotin can be increased when it is combined with Bisoprolol.
Isradipine Isradipine Isradipine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Fluvastatin Fluvastatin The excretion of Belantamab mafodotin can be decreased when combined with Fluvastatin.
Fluvoxamine Fluvoxamine Fluvoxamine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Nefazodone Nefazodone Nefazodone may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Losartan Losartan Losartan may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Nicardipine Nicardipine Nicardipine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Saquinavir Saquinavir The serum concentration of Belantamab mafodotin can be increased when it is combined with Saquinavir.
Glimepiride Glimepiride Glimepiride may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Gemcitabine Injection Gemcitabine Injection The serum concentration of Gemcitabine can be increased when it is combined with Belantamab mafodotin.
Indinavir Indinavir Indinavir may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Ritonavir Ritonavir The serum concentration of Belantamab mafodotin can be increased when it is combined with Ritonavir.
Valsartan Valsartan The excretion of Belantamab mafodotin can be decreased when combined with Valsartan.
Nelfinavir Nelfinavir Nelfinavir may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Fexofenadine Fexofenadine The serum concentration of Belantamab mafodotin can be increased when it is combined with Fexofenadine.
Loratadine Loratadine Loratadine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Carvedilol Carvedilol The serum concentration of Belantamab mafodotin can be increased when it is combined with Carvedilol.
Propafenone Propafenone The serum concentration of Belantamab mafodotin can be increased when it is combined with Propafenone.
Palivizumab Injection Palivizumab Injection The risk or severity of adverse effects can be increased when Palivizumab is combined with Belantamab mafodotin.
Efavirenz Efavirenz Efavirenz may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Sildenafil Sildenafil The serum concentration of Belantamab mafodotin can be increased when it is combined with Sildenafil.
Trastuzumab Injection Trastuzumab Injection The risk or severity of adverse effects can be increased when Trastuzumab is combined with Belantamab mafodotin.
Celecoxib Celecoxib Celecoxib may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Rosiglitazone Rosiglitazone Rosiglitazone may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.

Content provided by: AHFS® Patient Medication Information™. © Copyright, 2021. The American Society of Health-System Pharmacists